{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:56:02Z","timestamp":1774497362851,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.amepre.2017.01.027","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T11:15:44Z","timestamp":1490181344000},"page":"702-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Use of BRCA Mutation Test in the U.S., 2004\u20132014"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-2724","authenticated-orcid":false,"given":"Fangjian","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Hirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwyn","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyuba","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbey B.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5182","key":"10.1016\/j.amepre.2017.01.027_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"6559","key":"10.1016\/j.amepre.2017.01.027_bib2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.amepre.2017.01.027_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJM199601183340302","article-title":"Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer","volume":"334","author":"FitzGerald","year":"1996","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amepre.2017.01.027_bib4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nrclinonc.2010.166","article-title":"BRCA mutations in the management of breast cancer: the state of the art","volume":"7","author":"Narod","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"10.1016\/j.amepre.2017.01.027_bib5","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.amepre.2017.01.027_bib6","first-page":"1301","article-title":"Anglian Breast Cancer Study Group","volume":"83","year":"2000","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.amepre.2017.01.027_bib7","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.amepre.2017.01.027_bib8","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.amepre.2017.01.027_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMcp071286","article-title":"Clinical practice. Management of an inherited predisposition to breast cancer","volume":"357","author":"Robson","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amepre.2017.01.027_bib10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/0003-4819-143-5-200509060-00012","article-title":"Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force","volume":"143","author":"Nelson","year":"2005","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.amepre.2017.01.027_bib11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1200\/JCO.2013.51.4661","article-title":"Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative","volume":"32","author":"Wood","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.amepre.2017.01.027_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","article-title":"Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","volume":"115","author":"Meyer","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.amepre.2017.01.027_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000343790","article-title":"Primary care physician management, referral, and relations with specialists concerning patients at risk for cancer due to family history","volume":"16","author":"Wood","year":"2013","journal-title":"Public Health Genomics"},{"issue":"6","key":"10.1016\/j.amepre.2017.01.027_bib14","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1245\/s10434-012-2257-y","article-title":"Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers","volume":"19","author":"Drohan","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.amepre.2017.01.027_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility","volume":"28","author":"Robson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amepre.2017.01.027_bib16","series-title":"NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2016","year":"2016"},{"issue":"1","key":"10.1016\/j.amepre.2017.01.027_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.amepre.2017.01.027_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.amepre.2017.01.027_bib19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1055-9965.EPI-12-1280","article-title":"Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral","volume":"22","author":"Bellcross","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.amepre.2017.01.027_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/GIM.0b013e3182091ba4","article-title":"Underutilization of BRCA1\/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk","volume":"13","author":"Levy","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.amepre.2017.01.027_bib21","unstructured":"Libucha S, Petrozzi D. Optum. Clinformatics Data Mart training conducted at the University of Texas Medical Branch; Presentation by the dataset administrators from Eden Prairie, MN given to researchers at the University of Texas Medical Branch in Galveston, TX. August, 2015."},{"issue":"3","key":"10.1016\/j.amepre.2017.01.027_bib22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1542\/peds.2012-3680","article-title":"Ethical and policy issues in genetic testing and screening of children","volume":"131","year":"2013","journal-title":"Pediatrics"},{"issue":"17","key":"10.1016\/j.amepre.2017.01.027_bib23","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1016\/j.ejca.2006.04.025","article-title":"Cancer incidence in first-degree relatives of a population-based set of cases of early-onset breast cancer","volume":"42","author":"Rawal","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.amepre.2017.01.027_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/M13-1684","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation","volume":"160","author":"Nelson","year":"2014","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.amepre.2017.01.027_bib25","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.amepre.2017.01.027_bib26","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"Eisen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.amepre.2017.01.027_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ajog.2016.02.011","article-title":"Underuse of BRCA testing in patients with breast and ovarian cancer","volume":"214","author":"Wright","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.amepre.2017.01.027_bib28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jamaoncol.2015.5941","article-title":"BRCA1 and BRCA2 mutation testing in young women with breast cancer","volume":"2","author":"Rosenberg","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.amepre.2017.01.027_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3322\/caac.20128","article-title":"Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine","volume":"61","author":"Weitzel","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.amepre.2017.01.027_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ajog.2015.03.003","article-title":"Hereditary breast cancer: an update on risk assessment and genetic testing in 2015","volume":"213","author":"Stuckey","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.amepre.2017.01.027_bib31","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.6004\/jnccn.2014.0127","article-title":"Genetic\/familial high-risk assessment: breast and ovarian, version 1.2014","volume":"12","author":"Daly","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.amepre.2017.01.027_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.6004\/jnccn.2006.0016","article-title":"Genetic\/familial high-risk assessment: breast and ovarian","volume":"4","author":"Daly","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.amepre.2017.01.027_bib33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2010.0043","article-title":"Genetic\/familial high-risk assessment: breast and ovarian","volume":"8","author":"Daly","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.amepre.2017.01.027_bib34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/003335491412900611","article-title":"Coverage of clinical preventive services under the Affordable Care Act: from law to access","volume":"129","author":"Seiler","year":"2014","journal-title":"Public Health Rep"},{"issue":"9","key":"10.1016\/j.amepre.2017.01.027_bib35","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaoncol.2015.2340","article-title":"Cost-effectiveness of universal BRCA1\/2 screening: evidence-based decision making","volume":"1","author":"Long","year":"2015","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.amepre.2017.01.027_bib36","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jama.2014.12483","article-title":"Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award","volume":"312","author":"King","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2017.01.027_bib37","unstructured":"Color Test $249. https:\/\/getcolor.com\/kit\/how-it-works. Accessed September 9, 2016."},{"issue":"27","key":"10.1016\/j.amepre.2017.01.027_bib38","first-page":"603","article-title":"Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing\u2014Atlanta, Denver, Raleigh-Durham, and Seattle, 2003","volume":"53","author":"CDC","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.amepre.2017.01.027_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.GIM.0000156526.16967.7A","article-title":"Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally-occurring experiment","volume":"7","author":"Mouchawar","year":"2005","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.amepre.2017.01.027_bib40","first-page":"601","article-title":"Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization","volume":"11","author":"Mouchawar","year":"2005","journal-title":"Am J Manag Care"},{"issue":"11","key":"10.1016\/j.amepre.2017.01.027_bib41","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1158\/1055-9965.EPI-07-2879","article-title":"Too many referrals of low-risk women for BRCA1\/2 genetic services by family physicians","volume":"17","author":"White","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.amepre.2017.01.027_bib42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.gim.0000223544.68475.6c","article-title":"Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians\u2019 knowledge and practices","volume":"8","author":"Myers","year":"2006","journal-title":"Genet Med"},{"issue":"14","key":"10.1016\/j.amepre.2017.01.027_bib43","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2014.58.5885","article-title":"Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer","volume":"33","author":"Jagsi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.amepre.2017.01.027_bib44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"39","key":"10.1016\/j.amepre.2017.01.027_bib45","first-page":"14205","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A","volume":"111","author":"Gabai-Kapara","year":"2014"},{"issue":"1","key":"10.1016\/j.amepre.2017.01.027_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.bjc.6600008","article-title":"A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes","volume":"86","author":"Antoniou","year":"2002","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.amepre.2017.01.027_bib47","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/302320","article-title":"The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews","volume":"64","author":"Hartge","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.amepre.2017.01.027_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","article-title":"Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","volume":"28","author":"Metcalfe","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.amepre.2017.01.027_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.amepre.2017.01.027_bib50","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","article-title":"Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer","volume":"91","author":"Peto","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.amepre.2017.01.027_bib51","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P","article-title":"Frequency of BRCA1\/BRCA2 mutations in a population-based sample of young breast carcinoma cases","volume":"88","author":"Malone","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.amepre.2017.01.027_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/M13-2747","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.amepre.2017.01.027_bib53","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.3747\/co.22.2527","article-title":"Is it time to offer BRCA1 and BRCA2 testing to all Jewish women?","volume":"22","author":"Metcalfe","year":"2015","journal-title":"Curr Oncol"},{"issue":"9291","key":"10.1016\/j.amepre.2017.01.027_bib54","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","article-title":"Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease","volume":"358","year":"2001","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.amepre.2017.01.027_bib55","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","article-title":"Expanding the criteria for BRCA mutation testing in breast cancer survivors","volume":"28","author":"Kwon","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.amepre.2017.01.027_bib56","first-page":"103","article-title":"Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer","volume":"9","author":"Ziogas","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.amepre.2017.01.027_bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amepre.2010.09.027","article-title":"Awareness and utilization of BRCA1\/2 testing among U.S. primary care physicians","volume":"40","author":"Bellcross","year":"2011","journal-title":"Am J Prev Med"},{"issue":"23","key":"10.1016\/j.amepre.2017.01.027_bib58","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1002\/cncr.26166","article-title":"Reported referral for genetic counseling or BRCA 1\/2 testing among United States physicians: a vignette-based study","volume":"117","author":"Trivers","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.amepre.2017.01.027_bib59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/1875692111311020003","article-title":"Commercial opportunities and ethical pitfalls in personalized medicine: a myriad of reasons to revisit the Myriad Genetics saga","volume":"11","author":"So","year":"2013","journal-title":"Curr Pharmacogenomics Person Med"},{"issue":"9","key":"10.1016\/j.amepre.2017.01.027_bib60","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaoncol.2015.3048","article-title":"Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT Study","volume":"1","author":"Armstrong","year":"2015","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.amepre.2017.01.027_bib61","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2015.3269","article-title":"Genetic testing for BRCA mutations today and tomorrow\u2014about the ABOUT Study","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.amepre.2017.01.027_bib62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/PAP.0b013e3181c69442","article-title":"The physicians quality reporting initiative: measure development, implementation and current procedural terminology coding","volume":"17","author":"Myles","year":"2010","journal-title":"Adv Anat Pathol"},{"issue":"8","key":"10.1016\/j.amepre.2017.01.027_bib63","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/00001888-200008000-00021","article-title":"Knowledge, attitudes, and behaviors of Alabama\u2019s primary care physicians regarding cancer genetics","volume":"75","author":"Acton","year":"2000","journal-title":"Acad Med"},{"key":"10.1016\/j.amepre.2017.01.027_bib64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2296-11-45","article-title":"Primary care physicians\u2019 use of family history for cancer risk assessment","volume":"11","author":"Flynn","year":"2010","journal-title":"BMC Fam Pract"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379717300661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379717300661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T05:12:51Z","timestamp":1719119571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379717300661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0749379717300661"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2017.01.027","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of BRCA Mutation Test in the U.S., 2004\u20132014","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2017.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}